189 results on '"Richards, Hanno B."'
Search Results
2. Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head‐to‐Head Randomized Phase IIIb Study.
3. 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial
4. Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT
5. Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study
6. Immunopathogenesis of Environmentally Induced Lupus in Mice
7. Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study
8. Additional file 1 of Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis
9. Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data
10. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study
11. Pathogenesis of Autoantibody Production and Glomerulonephritis in Pristane-Treated Mice : An Inducible Model of SLE
12. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
13. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
14. 25529 Secukinumab demonstrates a consistent safety profile in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis over long term: Updated pooled safety analyses
15. Additional file 1 of Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT
16. P191 Secukinumab demonstrates a consistent safety profile in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis over long term: updated pooled safety analyses
17. Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study
18. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study
19. Effect of secukinumab, a fully human anti–interleukin-17a monoclonal antibody on C-reactive protein levels in patients with moderate to severe plaque psoriasis: Result of a dose-ranging study: P6396
20. Association of anti-nucleoprotein autoantibodies with upregulation of Type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus
21. LIST OF CONTRIBUTORS
22. ORIGINS OF ANTINUCLEAR ANTIBODIES
23. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus
24. Autoantibodies to RNA Helicase A: A New Serologic Marker of Early Lupus
25. Nucleolar Staining cannot be Used as a Screening Test for the Scleroderma Marker Anti–RNA Polymerase I/III Antibodies
26. Modulation of the immune response in pristane-induced lupus by expression of activation and inhibitory Fc receptors
27. Diagnostic Accuracy in Systemic Autoimmune Diseases
28. Circulating endothelial cells are associated with future vascular events in hemodialysis patients
29. The Interplay of Chemokines and Dendritic Cells in the Pathogenesis of Lupus Nephritis
30. Diagnostic Accuracy for Lupus and Other Systemic Autoimmune Diseases in the Community Setting
31. Strong Association of a Functional Polymorphism in the Monocyte Chemoattractant Protein 1 Promoter Gene With Lupus Nephritis
32. Nephritogenic autoantibodies but absence of nephritis in Il-12p35–deficient mice with pristane-induced lupus
33. Effect of an Exogenous Trigger on the Pathogenesis of Lupus in (NZB × NZW)F1 Mice
34. Interferon-γ is required for lupus nephritis in mice treated with the hydrocarbon oil pristane
35. Increased Prevalence of Autoantibodies to Ku Antigen in African American Versus White Patients With Systemic Lupus Erythematosus
36. Interleukin 6 Dependence of Anti-DNA Antibody Production: Evidence for Two Pathways of Autoantibody Formation in Pristane-induced Lupus
37. Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study.
38. Distinctive Immune Response Patterns of Human and Murine Autoimmune Sera to U1 Small Nuclear Ribonucleoprotein C Protein
39. Reversible dilated cardiomyopathy: An unusual case of thyrotoxicosis
40. Oral abstracts 3: RA Treatment and outcomesO13. Validation of jadas in all subtypes of juvenile idiopathic arthritis in a clinical setting
41. Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 MEASURE 3 Study.
42. Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
43. 172 Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: three-year results from Phase 3 trial, MEASURE 2
44. Secukinumab for the treatment of ankylosing spondylitis: comparative effectiveness results versus adalimumab using a matching-adjusted indirect comparison
45. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 2-year results from a phase 3 trial with subcutaneous loading and maintenance dosing (MEASURE 2)
46. Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis A Phase III Randomized Trial (MEASURE 1)
47. Secukinumab Reduces Sacroiliac Joint and Spinal Inflammation in Patients with Ankylosing Spondylitis: MRI Data from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Study (MEASURE 1)
48. Intravenous Loading and Subcutaneous Maintenance with Secukinumab Provides Sustained Improvement in Multiple Measures of Disease Activity in Subjects with Active Ankylosing Spondylitis: 52-week Data from the Phase 3 MEASURE 1 study
49. Secukinumab Safety and Tolerability in Patients With Active Psoriatic Arthritis: Pooled Safety Analysis of Two Phase 3, Randomized, Controlled Trials (FUTURE 1 and FUTURE 2)
50. Secukinumab improves multiple parameters of disease activity in subjects with active ankylosing spondylitis through 52 weeks of subcutaneous therapy: data from the phase 3 MEASURE 2 study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.